T he finding of elevated levels of tumor necrosis factor (TNF) in patients with chronic heart failure (CHF) suggested that inflammatory mediators might play a role in the pathophysiology of this syndrome. 1, 2 This hypothesis was strengthened by the finding that exogenous administration and transgenic overexpression of proinflammatory cytokines could mimic many aspects of the heart failure phenotype, including left ventricular remodeling and reduced survival, in experimental animals. [3] [4] [5] Etanercept is a recombinant human TNF receptor that binds to soluble (circulating) TNF and functionally inactivates TNF by preventing it from binding to its receptors on cell surface membranes. Thus far, treatment with etanercept has resulted in clinical improvements in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriasis. 6 -8 Preclinical studies showed that etanercept reversed some of the deleterious effects of TNF in vitro and in vivo. 3, 9 Moreover, phase I safety studies showed that a single intravenous infusion of etanercept was safe and well tolerated and led to an improvement in the functional status of heart failure patients. 10 In a subsequent study, biweekly injections of etanercept for 3 months resulted in a significant increase in left ventricular ejection fraction and a significant decrease in left ventricular volumes. 11 On the basis of the preclinical and clinical studies, 2 multicenter clinical trials were designed to test the effect of etanercept on patient functional status and morbidity/mortality.
Methods

Study Design
Two similar double-blind, randomized, placebo-controlled multicenter clinical trials were conducted, 1 in Europe, Israel, Australia, and New Zealand, known as Research into Etanercept CytOkine antagonism in VEntriculaR dysfunction (RECOVER), and the other in North America, known as Randomized Etanercept North AmerIcan Strategy to Study AntagoNism of CytokinEs (RENAISSANCE). The trials differed, importantly, only in the doses of etanercept used. In RECOVER, the patients were randomized on a 1:1:1 basis to placebo or etanercept 25 mg SC once weekly (QW) or twice weekly (BIW), whereas in RENAISSANCE, patients were randomized to placebo or etanercept 25 mg BIW or 25 mg 3 times weekly (TIW). Ͻ1  Ͻ1  Ͻ1  1 8  1 5  1 7   Male  75  77  81  77  77  81   Ischemic etiology  60  62  61  60  63  62   NYHA class   II  28  27  27  23  23  24   IIIA  43  45  45  47  47  47   IIIB  25  25  24  26  25  24   IV  3  3  3  4  5  5   Comorbidity   Hypertension  46  45  43  49  60  56   Diabetes mellitus  36  34  36  34  41  37   Medical treatment   Digoxin/digitalis  53  56  53  81  81  83   ACE inhibitor  85  83  87  82  77  79   ARB  13  14  12  16  23  19   ␤-Blocker  64  62  62  63  59  59   K-sparing diuretic  37  44  44  34  37  32   Any diuretic  99  99  99  99  98  100 LVEF indicates left ventricular ejection fraction; SBP, systolic blood pressure; DBP, diastolic blood pressure; and ARB, angiotensin-receptor blocker.
Values are percentages except where otherwise noted.
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The intent was for each trial to enroll 900 patients ( Figure 1 ). The primary end point in RENAISSANCE and RECOVER was a change in clinical status from baseline to 24 weeks. This end point is based on a composite score, wherein patients are considered improved, worsened, or unchanged on the basis of death, CHF hospitalization, New York Heart Association (NYHA) class, and patient global assessment, as detailed previously. 12 A prespecified analysis of the effect of etanercept on longer-term morbidity/mortality was also planned. This analysis, which was referred to as the Randomized EtaNErcept Worldwide evALuation (RENEWAL), combined the BIW treatment arm of RECOVER with the BIW and TIW arms of RENAISSANCE and compared these with the pooled placebo arms from both studies, with an anticipated total of 1500 patients. The primary end point of RENEWAL was the composite of death (of all causes) or hospitalization for or with CHF. The RENEWAL analysis was event driven (see statistical analysis). Secondary end points included all-cause mortality and the total number of hospitalizations and emergency room visits for or with worsening CHF, as well as, at 24 weeks, change in NYHA class, patient global assessment, and quality of life.
Patients
The main inclusion criteria were age 18 to 85 years; NYHA class II to IV; ischemic or nonischemic etiology; left ventricular ejection fraction Յ0.30; stable doses of diuretic, ACE inhibitor (unless not tolerated), and ␤-blocker and/or spironolactone (if taking) for Ն3 months; and 6-minute walk distance of Ͻ375 m (or Ͻ425 m if hospitalized for CHF within previous 6 months). The main exclusion criteria were severe infection within 1 month, surgically correctable causes of heart failure, other serious illness, acute myocardial infarction or hospitalization (3 months), and recent (3 months) or planned surgery/coronary revascularization. The studies received ethics approval in all participating centers, and all patients gave written informed consent.
Statistical Analyses
In RECOVER and RENAISSANCE, the clinical composite score was analyzed with a Cochran-Mantel-Haenszel test. The statistical assumptions in RECOVER were that in the placebo group, 40% of the patients would be worse, 42% would remain unchanged, and 18% would be improved, and in the treatment group (QW and BIW etanercept), 28% of the patients would be worse, 42% would remain unchanged, and 30% would be improved. There was 90% power for the primary hypothesis test of 25 mg BIW versus placebo and 81% power for the conditional primary hypothesis test of 25 mg QW versus placebo, both tested at the 2-sided 0.04 level. The statistical assumptions in RENAISSANCE were that in the placebo group, 25% of the patients would be worse, 55% would remain unchanged, and 20% would be improved, and in the treatment group (BIW and TIW etanercept), 17% of the patients would be worse, 53% would remain unchanged, and 30% would be improved. There was 84% power for each comparison of an etanercept treatment arm to placebo when controlling the overall type I error rate at 0.04. In the RENEWAL trial, using a stratified log-rank analysis, 389 events would provide 90% power for a 2-sided 0.01 level test to detect a 32.4% relative reduction in risk for this end point, when the combined BIW and TIW etanercept treatment arms were compared with placebo. To control the overall type I error rate within each study at 0.05, analyses of the clinical status composite were conducted at the 2-sided 0.04 level, and the combined analysis of all-cause mortality or CHF hospitalization was conducted at the 2-sided 0.01 level. The log-rank statistic for the RENEWAL analysis was stratified by study, baseline ␤-blocker status, and NYHA functional class.
Safety Monitoring and Stopping Guidelines
A single independent Data Monitoring Committee (DMC) monitored both RENAISSANCE and RECOVER. The DMC could recommend modifications to the protocols to enhance patient safety or quality of trial conduct. Early termination of the studies could be recommended if there was strong evidence that etanercept would show no benefit at the end of the study for the clinical composite end point. Such evidence was defined as having sufficiently unfavorable interim results in the 4 pairwise comparisons with placebo (by comparison of each of the 2 dose groups with placebo in both RECOVER and RENAISSANCE) that the conditional probability for achieving a positive effect on the clinical composite end point (if one continued to assume the protocol-specified targeted level of benefit) was Ͻ0.25 for each of these 4 pairwise comparisons. Early termination could also be recommended by the DMC for conclusive interim results on the morbidity/mortality end point in RENEWAL, either because interim data for the combined end point of mortality and hospitalization for heart failure would be sufficiently unfavorable as to rule out a 10% reduction in relative risk or because interim data for all-cause mortality would be sufficiently favorable as to establish benefit, where both of these assessments would be guided by use of the O'Brien-Fleming monitoring boundary.
Results
Patients Enrolled
Between June 1999 and December 2000, a total of 1123 patients from 194 centers were enrolled in RECOVER. In RENAISSANCE, 925 patients from 105 centers were randomized between March 1999 and January 2001. The baseline characteristics of the patients are summarized in Table 1 . The placebo and etanercept groups in each study were generally well matched, although there were imbalances between treatment groups for diabetes in both studies. There was also an imbalance in the number of patients with a history 
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Early Termination of Studies
On March 22, 2001, the DMC recommended termination of both studies because the prespecified criteria for stopping due to lack of benefit were met in the RECOVER and RENAIS-SANCE studies and the RENEWAL analysis. The median time from randomization to the last visit was 5.7 months in RECOVER and 12.9 months in RENAISSANCE. At the time the studies were closed, 37% and 73% of the patients in RECOVER and RENAISSANCE, respectively, had completed the 24-week evaluation. One percent or less of any treatment group of RECOVER or RENAISSANCE was lost to follow-up for assessment of vital status, and 0.4% and 0.9% of patients withdrew consent for evaluation of clinical status in RECOVER and RENAISSANCE, respectively. Figure 2 shows that there were not significant differences between placebo and etanercept with respect to change in the clinical composite score from baseline to 24 weeks (or the last evaluated visit before study stoppage) in either RECOVER (Pϭ0.34 overall; Pϭ0.76 QW; Pϭ0.27 BIW) or RENAIS-SANCE (Pϭ0.17 overall; Pϭ0.07 BIW; Pϭ0.17 TIW). In RENAISSANCE, there was a higher proportion (29%, Pϭ0.046) of patients given etanercept 25 mg BIW than placebo patients (20%) in the "worsened" category at 24 weeks; however, this difference was not observed in RECOVER.
Primary End Point in RENAISSANCE and RECOVER
Outcome of Death or CHF Hospitalization in RENEWAL
For the death and CHF hospitalization end point, the log-rank analysis was stratified by trial, baseline NYHA class, and ␤-blocker use and included 682 placebo patients (309 from RENAISSANCE and 373 from RECOVER) and the 991 etanercept patients (375 BIW patients from RECOVER and 308 BIW and 308 TIW patients from RENAISSANCE). In RENAISSANCE, there were 100 events in 309 patients in the placebo group and 228 events in 616 patients in the combined etanercept groups; in RECOVER, there were 66 events in 373 patients in the placebo group and 60 events in 375 patients in the BIW etanercept group. These data yielded an estimated etanercept-to-placebo relative risk of 1.1 (95% CI 0.91 to 1.33; Pϭ0.33; Figure 3) . Hence, the results were sufficiently unfavorable as to exclude a 10% reduction in the rate of death or CHF hospitalization with etanercept.
Secondary Outcomes in RENEWAL
With regard to overall mortality, in RENAISSANCE, there were 44 deaths in 309 patients in the placebo group and 116 deaths in 616 patients in the combined etanercept groups; in RECOVER, there were 33 deaths in 373 patients in the placebo group and 27 deaths in 375 patients in the BIW etanercept group. These data yielded an estimated etanerceptto-placebo relative risk of 1.13 (95% CI 0.86 to 1.50; Pϭ0.39; Figure 4 ). There were no significant differences in any of the other secondary outcomes. Figure 5 summarizes the RENEWAL subgroup analyses. Overall, there were no significant differences between treatments for any of the subgroups. Table 3 summarizes the incidence of adverse events that occurred in both trials. Adverse events that occurred in more than 10% of patients overall in the RENAISSANCE trial were upper respiratory tract infections, dizziness, injectionsite reaction, pain, diarrhea, chest pain, bronchitis, headache, flu syndrome, constipation, and cough. Of these events, injection-site reaction, bronchitis, and constipation occurred statistically significantly (PϽ0.05) more frequently in patients receiving etanercept than in those given placebo. In the RECOVER trial, adverse events that occurred in more than 5% of patients were upper respiratory infection, injection-site reaction, bronchitis, dizziness, pneumonia, chest pain, abdominal pain, angina pectoris, flu syndrome, increased cough, and dyspnea; there were no statistically significant differences (PϾ0.10) among the 3 treatment groups for these events. Table 4 summarizes the incidence of serious and nonserious infections in both trials and shows a trend (Pϭ0.067) toward more infections, overall, in the etanercept-treated patients in RECOVER, although this was not observed in RENAISSANCE. There was not an increase in serious infections in either study.
RENEWAL Subgroup Analyses
Adverse Events and Safety
Discussion
The clinical trials reported here did not demonstrate a benefit of etanercept in patients with heart failure despite the wealth of preclinical and preliminary clinical data suggesting a therapeutic role for TNF antagonism in this condition. Although the reasons for this lack of benefit of etanercept are not known, there are several possible explanations. One possibility is that proinflammatory cytokines do not play a deleterious role in the pathophysiology of CHF. A second possibility is that the doses of etanercept that we used were not sufficient to neutralize circulating and/or myocardial tissue levels of TNF. A third possibility is that the targeted approach that was taken was not sufficient to disrupt the network of inflammatory mediators (eg, interleukin-1␤, interleukin-6, and nitric oxide) that are activated in heart failure. 13 Targeted anticytokine treatment with etanercept has been beneficial in some (eg, rheumatoid arthritis, ankylosing spondylitis, and psoriasis 6 -8 ) but not all (eg, Crohn's disease and systemic sepsis 14, 15 ) conditions in which TNF is thought to play an important pathophysiological role. It is not possible to definitively address these latter 2 possibilities because neither circulating levels of inflammatory mediators nor measures of TNF bioactivity were analyzed systematically in RECOVER and RENAISSANCE. A fourth possibility is that the short-term benefits of etanercept observed in the earlier small phase I studies in CHF were offset in the long term by the ability of etanercept to stabilize biologically active (homotrimeric) TNF, thereby acting as an TNF agonist. 16 The observation that there was a higher proportion of patients in the worsened category in RENAISSANCE, in which patients were exposed to etanercept for the longest time, is consistent with this point of view. A final consideration suggested by experimental studies is that physiological levels of TNF are necessary for cardiovascular homeostasis. 17, 18 Accordingly, sustained lowering of TNF may have contributed to the higher proportion of patients in the worsened category because of loss of the beneficial aspects of cytokine signaling.
The results of the present study need to be discussed in light of the recently reported ATTACH (Anti-TNF-␣ in Congestive Heart Failure) trial, 19 a smaller study of 150 patients that used a chimeric anti-TNF antibody that exerts anti-inflammatory effects by binding to and neutralizing circulating TNF, as well as lysing TNF-expressing cells through complement fixation. In ATTACH, there was a significant increase in death and heart failure hospitalization at 28 weeks in the patients who received infliximab 10 mg/kg. Although we cannot discount the possibility that the worsening heart failure observed in the ATTACH trial and the suggestion of worsening heart failure outcome seen in the RENAISSANCE trial both may have been related to excessive TNF antagonism or loss of the beneficial aspects of cytokine signaling, there are other possible explanations, including "TNF rebound" 20 and complement fixation, that may have contributed to worsening heart failure outcomes in the ATTACH trial. However, precise mechanistic explanations for the differences in outcomes in the ATTACH and RENEWAL trials are not known, and the above suggestions are speculative.
A potential concern with etanercept was increased susceptibility to infection or decreased resistance to infection. Although there was a trend toward increased infections in patients in RECOVER, this was not observed in RENAIS-SANCE, wherein the patients were treated for longer periods of time. Moreover, there was no significant increase in serious infections in either trial (Table 4) . Of note, no 
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significant increase in infections has been seen in randomized controlled trials with etanercept in patients with rheumatoid arthritis and psoriasis. Adverse events that were observed more frequently and that were statistically significant occurred only in the treatment arm of RENAISSANCE and included injection-site reaction, bronchitis, and constipation.
In conclusion, the results of RENEWAL were sufficiently unfavorable as to rule out a clinically relevant benefit of targeted anticytokine therapy with the soluble TNF antagonist etanercept on the rate of death or CHF hospitalization in CHF. Although one interpretation of the disappointing results of the recent clinical trials with targeted anticytokine therapy in heart failure is that inflammatory mediators are not viable targets in heart failure, a countervailing point of view is that we simply have not targeted proinflammatory mediators with agents that can be used safely in the context of heart failure, 21 or alternatively, that targeting a single component of the inflammatory cascade is not sufficient in a disease as complex as heart failure. Moreover, these studies do not exclude the possibility that there exists a select group of patients in whom TNF antagonism may be beneficial. Whether broaderspectrum anti-inflammatory strategies (eg, statins, immunoadsorption, or immune modulation therapy) will have any added value in heart failure is currently being addressed in ongoing clinical trials. 
